MCID: MDS019
MIFTS: 35

Mediastinal Malignant Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases

Aliases & Classifications for Mediastinal Malignant Lymphoma

MalaCards integrated aliases for Mediastinal Malignant Lymphoma:

Name: Mediastinal Malignant Lymphoma 12 15
Lymphoma of Mediastinum 12
Mediastinal Lymphoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:6868
NCIt 50 C6633
UMLS 73 C1334665

Summaries for Mediastinal Malignant Lymphoma

MalaCards based summary : Mediastinal Malignant Lymphoma, also known as lymphoma of mediastinum, is related to lymphoma and lymphosarcoma. An important gene associated with Mediastinal Malignant Lymphoma is EPHA7 (EPH Receptor A7), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Antibodies and Antibodies, Monoclonal have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and colon, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Mediastinal Malignant Lymphoma

Diseases related to Mediastinal Malignant Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
# Related Disease Score Top Affiliating Genes
1 lymphoma 30.3 BCL11A BCL6 PAX5 REL TNFRSF8
2 lymphosarcoma 10.3
3 chromosome 2p16.1-p15 deletion syndrome 10.2 BCL11A REL XPO1
4 nodular lymphocyte predominant hodgkin lymphoma 10.2 BCL6 PAX5
5 primary central nervous system lymphoma 10.2 BCL6 CD274 PAX5
6 breast lymphoma 10.1 BCL6 CD79A
7 composite lymphoma 10.1 BCL6 PAX5
8 mediastinal gray zone lymphoma 10.1 CD274 EPHA7 HOXA5 PAX5
9 malignant leydig cell tumor 10.1 PAX5 TNFRSF8
10 bladder lymphoma 10.1 CD79A PAX5
11 gray zone lymphoma 10.1 BCL11A CD274 CD79A PAX5
12 lymphoma, hodgkin, classic 10.1 BCL6 CD79A PAX5
13 sternum cancer 10.1 FUT4 TNFRSF8
14 primary mediastinal b-cell lymphoma 10.1 BCL11A BCL6 REL XPO1
15 intraocular lymphoma 10.1 BCL6 PAX5
16 pediatric lymphoma 10.1 CD79A DAPK1 TNFRSF8
17 t-cell/histiocyte rich large b cell lymphoma 10.1 BCL6 TNFRSF8
18 colon lymphoma 10.0 BCL6 CD79A TNFRSF8
19 reticulosarcoma 10.0 BCL6 PAX5 TNFRSF8
20 primary mediastinal large b-cell lymphoma 10.0 BCL6 CD274 JAK2 XPO1
21 lymphatic system cancer 10.0 BCL6 CD79A TNFRSF8
22 epidural neoplasm 10.0 BCL6 FUT4 TNFRSF8
23 myasthenic syndrome, congenital, 14 10.0 CD274 JAK2 PDCD1LG2
24 lung lymphoma 10.0 BCL6 CD79A PAX5 TNFRSF8
25 leukocyte disease 10.0 BCL6 CD79A PAX5 TNFRSF8
26 epstein-barr virus-associated gastric carcinoma 10.0 CD274 JAK2 PDCD1LG2
27 diffuse large b-cell lymphoma 9.9 BCL6 CD79A REL TNFRSF8
28 b-cell lymphomas 9.9 BCL6 PAX5 REL TNFRSF8
29 testicular infarct 9.9 FUT4 TNFRSF8
30 lymphoma, non-hodgkin, familial 9.8 BCL6 CD79A JAK2 PAX5 TNFRSF8
31 reticulohistiocytic granuloma 9.8 FSCN1 FUT4 TNFRSF8
32 hematologic cancer 9.7 BCL6 IL3RA JAK2 PAX5 TNFRSF8
33 hodgkin's lymphoma, lymphocytic depletion 9.5 CD79A FSCN1 FSCN3 FUT4 PAX5 TNFRSF8

Graphical network of the top 20 diseases related to Mediastinal Malignant Lymphoma:



Diseases related to Mediastinal Malignant Lymphoma

Symptoms & Phenotypes for Mediastinal Malignant Lymphoma

GenomeRNAi Phenotypes related to Mediastinal Malignant Lymphoma according to GeneCards Suite gene sharing:

26 (show all 14)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.22 DAPK1
2 Decreased viability GR00106-A-0 10.22 MAOA PAX5
3 Decreased viability GR00221-A-1 10.22 DAPK1
4 Decreased viability GR00221-A-2 10.22 JAK2 REL
5 Decreased viability GR00221-A-3 10.22 EPHA7 REL
6 Decreased viability GR00221-A-4 10.22 DAPK1 REL
7 Decreased viability GR00301-A 10.22 REL
8 Decreased viability GR00342-S-1 10.22 DAPK1
9 Decreased viability GR00342-S-2 10.22 EPHA7
10 Decreased viability GR00342-S-3 10.22 EPHA7
11 Decreased viability GR00381-A-1 10.22 CD79A PDCD1LG2
12 Decreased viability GR00381-A-3 10.22 CD79A
13 Decreased viability GR00402-S-2 10.22 BCL11A BCL6 CD274 CD79A DAPK1 EPHA7
14 no effect GR00402-S-1 9.62 BCL11A BCL6 CD274 CD79A DAPK1 EPHA7

MGI Mouse Phenotypes related to Mediastinal Malignant Lymphoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.93 BCL11A BCL6 CD274 CD79A DAPK1 FSCN1
2 hematopoietic system MP:0005397 9.8 BCL11A BCL6 CD274 CD79A FUT4 GPR15
3 immune system MP:0005387 9.5 BCL11A BCL6 CD274 CD79A FSCN1 FUT4

Drugs & Therapeutics for Mediastinal Malignant Lymphoma

Drugs for Mediastinal Malignant Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Antibodies Phase 2,Phase 1
2 Antibodies, Monoclonal Phase 2,Phase 1
3 Immunoglobulins Phase 2,Phase 1
4 Immunologic Factors Phase 2,Phase 1,Not Applicable
5
rituximab Approved Phase 1,Not Applicable 174722-31-7 10201696
6
Repaglinide Approved, Investigational Phase 1 135062-02-1 65981
7
Miconazole Approved, Investigational, Vet_approved Phase 1 22916-47-8 4189
8
Omeprazole Approved, Investigational, Vet_approved Phase 1 73590-58-6 4594
9
Fluconazole Approved, Investigational Phase 1 86386-73-4 3365
10 Blinatumomab Approved, Investigational Phase 1 853426-35-4
11
Lenalidomide Approved Phase 1 191732-72-6 216326
12
Fludarabine Approved Phase 1 75607-67-9, 21679-14-1 30751
13
Nicotinamide Approved, Investigational Phase 1 98-92-0 936
14
Cyclophosphamide Approved, Investigational Phase 1 6055-19-2, 50-18-0 2907
15
Pembrolizumab Approved Phase 1 1374853-91-4
16
Niacin Approved, Investigational, Nutraceutical Phase 1 59-67-6 938
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
18 Hypoglycemic Agents Phase 1
19 Cytochrome P-450 CYP2C19 Inhibitors Phase 1
20 Hormones Phase 1
21 Cytochrome P-450 CYP3A Inhibitors Phase 1
22 Proton Pump Inhibitors Phase 1
23 Steroid Synthesis Inhibitors Phase 1
24 Anti-Ulcer Agents Phase 1
25 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 1
26 Antifungal Agents Phase 1
27 Anti-Infective Agents Phase 1
28 Hormone Antagonists Phase 1
29 Antacids Phase 1
30 Cytochrome P-450 CYP2C9 Inhibitors Phase 1
31 Cytochrome P-450 Enzyme Inhibitors Phase 1
32 Gastrointestinal Agents Phase 1
33 Angiogenesis Inhibitors Phase 1
34 Anti-Bacterial Agents Phase 1
35 Immunosuppressive Agents Phase 1
36 Muromonab-CD3 Phase 1
37 Angiogenesis Modulating Agents Phase 1
38 Antibodies, Bispecific Phase 1
39 Pharmaceutical Solutions Phase 1
40 Antineoplastic Agents, Alkylating Phase 1
41 Vasodilator Agents Phase 1
42 Alkylating Agents Phase 1
43 Vitamin B9 Phase 1
44 Lipid Regulating Agents Phase 1
45 Vitamins Phase 1
46 Vitamin B3 Phase 1
47 Antimetabolites Phase 1
48 Micronutrients Phase 1
49 Vitamin B Complex Phase 1
50 Folate Phase 1

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL Completed NCT02423291 Phase 2 Brentuximab Vedotin
2 Radiotherapy Delivery in Deep Inspiration for Pediatric Patients Recruiting NCT03315546 Phase 1, Phase 2
3 Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients Recruiting NCT03028103 Phase 1 Tazemetostat;Fluconazole;Omeprazole;Repaglinide
4 Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma Recruiting NCT02568553 Phase 1 Lenalidomide
5 Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors Recruiting NCT03010982 Phase 1 Tazemetostat and [14C] Tazemetostat
6 Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Recruiting NCT03019666 Phase 1
7 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT02950220 Phase 1 Ibrutinib
8 Radiotherapy in Primary Mediastinal Lymphoma Completed NCT01230008
9 Breathing Adapted Radiotherapy for Mediastinal Lymphoma Completed NCT00928096
10 Cardiotoxicity of Radiation Therapy (CTRT) Completed NCT02769299
11 A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma Completed NCT00944567
12 Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma Recruiting NCT01599559 Not Applicable

Search NIH Clinical Center for Mediastinal Malignant Lymphoma

Genetic Tests for Mediastinal Malignant Lymphoma

Anatomical Context for Mediastinal Malignant Lymphoma

MalaCards organs/tissues related to Mediastinal Malignant Lymphoma:

41
B Cells, Lung, Colon, Pancreas, T Cells

Publications for Mediastinal Malignant Lymphoma

Articles related to Mediastinal Malignant Lymphoma:

# Title Authors Year
1
Takayasu's arteritis misdiagnosed as mediastinal malignant lymphoma: a case report and review of the literature. ( 24977018 )
2014
2
Posterior mediastinal malignant lymphoma mimicking a neurogenic tumor. ( 23336918 )
2013
3
Mediastinal malignant lymphoma difficult to diagnose: a patient report. ( 24031133 )
2011
4
Magnetic resonance imaging and 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: a prospective pilot study. ( 9220410 )
1996
5
Magnetic resonance imaging and 67gallium scan in mediastinal malignant lymphoma: a prospective pilot study. ( 8075050 )
1994
6
Primary mediastinal malignant lymphoma. ( 1550890 )
1992
7
Mediastinal malignant lymphoma complicated with esophagobronchial fistula: successfully treated case. ( 3694829 )
1987
8
Mediastinal malignant lymphoma. ( 5537415 )
1970
9
An unusual case of paroxysmal auricular fibrillation due to mediastinal malignant lymphoma. ( 14818942 )
1951

Variations for Mediastinal Malignant Lymphoma

Expression for Mediastinal Malignant Lymphoma

Search GEO for disease gene expression data for Mediastinal Malignant Lymphoma.

Pathways for Mediastinal Malignant Lymphoma

GO Terms for Mediastinal Malignant Lymphoma

Cellular components related to Mediastinal Malignant Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 CD274 CD79A IL3RA PDCD1LG2
2 endomembrane system GO:0012505 8.8 CD274 JAK2 PDCD1LG2

Biological processes related to Mediastinal Malignant Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.43 BCL6 EPHA7 HMOX1 HOXA5 JAK2 TNFRSF8
2 negative regulation of interleukin-10 production GO:0032693 9.32 CD274 PDCD1LG2
3 negative regulation of activated T cell proliferation GO:0046007 9.26 CD274 PDCD1LG2
4 negative regulation of mast cell cytokine production GO:0032764 9.16 BCL6 HMOX1
5 cytokine-mediated signaling pathway GO:0019221 9.1 BCL6 FSCN1 HMOX1 IL3RA JAK2 MAOA

Sources for Mediastinal Malignant Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....